Trials / Completed
CompletedNCT03470233
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB
Post-marketing Registry to Assess Usage Information, Safety and Effectiveness of Deltyba® Tablets in Korean Patients With Pulmonary Multi-drug Resistant Tuberculosis (MDR-TB)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 149 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Deltyba Registry aims to collect the usage information of Deltyba which could be a factor of developing resistance in actual clinical settings.
Detailed description
To collect the usage information of Deltyba in actual clinical settings for the management of resistance to Deltyba
Conditions
Timeline
- Start date
- 2017-05-25
- Primary completion
- 2021-06-21
- Completion
- 2021-06-21
- First posted
- 2018-03-19
- Last updated
- 2021-09-17
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03470233. Inclusion in this directory is not an endorsement.